# GCLM

## Overview
The GCLM gene encodes the glutamate-cysteine ligase modifier subunit, a crucial component of the enzyme glutamate-cysteine ligase (GCL), which plays a pivotal role in the biosynthesis of glutathione, a major cellular antioxidant. The GCL enzyme is a heterodimer consisting of a catalytic subunit (GCLC) and the modifier subunit (GCLM), with the latter enhancing the enzyme's efficiency and stability. GCLM is integral to maintaining cellular redox balance and protecting cells from oxidative stress, particularly in erythrocytes. It is involved in various cellular processes, including detoxification and immune responses, by modulating glutathione levels. The protein's interaction with GCLC is essential for its function, and its expression levels have significant implications in cancer biology, where it is often upregulated, contributing to tumor progression and poor prognosis (Föller2013Functional; Harris2015Glutathione; Franklin2009Structure).

## Function
The GCLM gene encodes the modifier subunit of the enzyme glutamate-cysteine ligase (GCL), which is essential for the synthesis of glutathione, a major antioxidant in cells. GCL is a heterodimer composed of a catalytic subunit (GCLC) and a modifier subunit (GCLM). While the catalytic subunit can function independently, the presence of GCLM optimizes the enzyme's activity by lowering the K_M value for the substrate glutamate and increasing the K_i value for glutathione (GSH), thereby enhancing glutathione synthesis (Föller2013Functional; Kendig2011Lipid).

In healthy human cells, GCLM plays a critical role in maintaining cellular redox balance by supporting the production of glutathione, which is crucial for protecting cells from oxidative stress. This function is particularly important in erythrocytes, which are constantly exposed to oxidative stress due to their role in oxygen transport. Adequate levels of glutathione help prevent oxidative damage and maintain erythrocyte integrity (Föller2013Functional). The activity of GCLM is also linked to various cellular processes, including detoxification and immune responses, by influencing glutathione levels and cellular redox states (Kendig2011Lipid).

## Clinical Significance
Alterations in the expression of the GCLM gene have significant clinical implications, particularly in cancer. GCLM is involved in the synthesis of glutathione (GSH), a critical antioxidant that helps manage reactive oxygen species (ROS) levels in cells. In cancer, GCLM expression is often upregulated, contributing to tumor progression and poor prognosis. In mammary tumors, disruption of GCLM in mice leads to delayed tumor onset and reduced tumor burden, suggesting its role in cancer initiation and progression (Harris2015Glutathione). High GCLM mRNA levels in human tumors are associated with lower relapse-free and overall survival rates in cancer patients (Harris2015Glutathione).

In bladder cancer (BLCA), GCLM acts as an oncogene, correlating with unfavorable prognosis and increased cell proliferation. The compound MTX-211 has been shown to reduce GCLM expression, leading to increased ROS levels and decreased GSH synthesis, which can enhance the effectiveness of chemotherapeutic agents like cisplatin (Hu2023MTX211). GCLM is also linked to immune infiltration in BLCA, serving as an immunological biomarker and influencing the tumor immune microenvironment (Wang2022Systematical). These findings highlight the potential of targeting GCLM and its associated pathways as a therapeutic strategy in cancer treatment.

## Interactions
The glutamate-cysteine ligase modifier subunit (GCLM) primarily interacts with the catalytic subunit GCLC to form the glutamate-cysteine ligase (GCL) holoenzyme, which is essential for glutathione biosynthesis. This interaction enhances the catalytic efficiency and stability of the enzyme complex (Franklin2009Structure). GCLM is sensitive to aggregation in vitro without GCLC, indicating a stabilizing interaction between the two subunits (Franklin2009Structure). 

In the context of oxidative stress, GCLM undergoes dose-dependent multimerization induced by hydrogen peroxide (H2O2), suggesting that oxidative conditions can influence its interaction dynamics (Franklin2009Structure). The formation of the GCL holoenzyme involves intermolecular disulfide bonds, which can be dissociated by reducing agents, indicating a redox switch mechanism that regulates the interaction between GCLC and GCLM (Franklin2009Structure).

While GCLM has a domain homologous to aldo-keto reductases, suggesting potential interactions with NADPH, specific physical interactions with other proteins or nucleic acids have not been detailed in the provided context (Franklin2009Structure). The role of GCLM in cellular redox balance and its regulation by the Nrf2 pathway has been noted, but specific interactions beyond its association with GCLC are not described (Lu2016An).


## References


[1. (Lu2016An) Meng-Chen Lu, Jian-Ai Ji, Yong-Lin Jiang, Zhi-Yun Chen, Zhen-Wei Yuan, Qi-Dong You, and Zheng-Yu Jiang. An inhibitor of the keap1-nrf2 protein-protein interaction protects ncm460 colonic cells and alleviates experimental colitis. Scientific Reports, May 2016. URL: http://dx.doi.org/10.1038/srep26585, doi:10.1038/srep26585. This article has 78 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/srep26585)

[2. (Hu2023MTX211) Bing Hu, Ru Chen, Ming Jiang, Situ Xiong, An Xie, Xiaoqiang Liu, and Bin Fu. Mtx-211 inhibits gsh synthesis through keap1/nrf2/gclm axis and exerts antitumor effects in bladder cancer. International Journal of Molecular Sciences, 24(8):7608, April 2023. URL: http://dx.doi.org/10.3390/ijms24087608, doi:10.3390/ijms24087608. This article has 5 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms24087608)

[3. (Föller2013Functional) M Föller, I S Harris, A Elia, R John, F Lang, T J Kavanagh, and T W Mak. Functional significance of glutamate–cysteine ligase modifier for erythrocyte survival in vitro and in vivo. Cell Death &amp; Differentiation, 20(10):1350–1358, June 2013. URL: http://dx.doi.org/10.1038/cdd.2013.70, doi:10.1038/cdd.2013.70. This article has 25 citations.](https://doi.org/10.1038/cdd.2013.70)

[4. (Wang2022Systematical) Song Wang, He Wang, Shaoxing Zhu, and Fangyin Li. Systematical analysis of ferroptosis regulators and identification of gclm as a tumor promotor and immunological biomarker in bladder cancer. Frontiers in Oncology, October 2022. URL: http://dx.doi.org/10.3389/fonc.2022.1040892, doi:10.3389/fonc.2022.1040892. This article has 5 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fonc.2022.1040892)

[5. (Harris2015Glutathione) Isaac S. Harris, Aislinn E. Treloar, Satoshi Inoue, Masato Sasaki, Chiara Gorrini, Kim Chung Lee, Ka Yi Yung, Dirk Brenner, Christiane B. Knobbe-Thomsen, Maureen A. Cox, Andrew Elia, Thorsten Berger, David W. Cescon, Adewunmi Adeoye, Anne Brüstle, Sam D. Molyneux, Jacqueline M. Mason, Wanda Y. Li, Kazuo Yamamoto, Andrew Wakeham, Hal K. Berman, Rama Khokha, Susan J. Done, Terrance J. Kavanagh, Ching-Wan Lam, and Tak W. Mak. Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression. Cancer Cell, 27(2):211–222, February 2015. URL: http://dx.doi.org/10.1016/j.ccell.2014.11.019, doi:10.1016/j.ccell.2014.11.019. This article has 744 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.ccell.2014.11.019)

[6. (Kendig2011Lipid) Eric L. Kendig, Ying Chen, Mansi Krishan, Elisabet Johansson, Scott N. Schneider, Mary Beth Genter, Daniel W. Nebert, and Howard G. Shertzer. Lipid metabolism and body composition in gclm(−/−) mice. Toxicology and Applied Pharmacology, 257(3):338–348, December 2011. URL: http://dx.doi.org/10.1016/j.taap.2011.09.017, doi:10.1016/j.taap.2011.09.017. This article has 55 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.taap.2011.09.017)

[7. (Franklin2009Structure) Christopher C. Franklin, Donald S. Backos, Isaac Mohar, Collin C. White, Henry J. Forman, and Terrance J. Kavanagh. Structure, function, and post-translational regulation of the catalytic and modifier subunits of glutamate cysteine ligase. Molecular Aspects of Medicine, 30(1–2):86–98, February 2009. URL: http://dx.doi.org/10.1016/j.mam.2008.08.009, doi:10.1016/j.mam.2008.08.009. This article has 318 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.mam.2008.08.009)